Latest filing published 29 Apr 2021 for Theravance Biopharma, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Filings by George M. Whitesides span 4 companies, the busiest being Rohm & Haas Co, Innoviva, Inc. and Theravance Biopharma, Inc. Over a trading history stretching from 9 January 2006 to 27 April 2021, the count stands at 41 filings.
No open-market sale appears; the market trades are 1 purchase worth €84k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 34 share grants and 1 option exercise.
The record was last updated on 29 April 2021 with a share grant in Theravance Biopharma, Inc. The last insider purchase was made public on 14 August 2017, 3,357 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 39 declarations